FiercePharmaOriginal article
{"a":[{"_":"Trump GLP-1 update teases blockbuster annual sales for Lilly from Medicare program: analyst","$":{"href":"/pharma/trump-glp-1-update-suggests-blockbuster-annual-sales-lilly-medicare-program-analyst","hreflang":"en"}}]}
PartnershipPositive
AI Analysis
Summary
The Trump administration's MFN drug pricing deal with Eli Lilly and Novo Nordisk has led to Medicare launching a bridge program offering weight loss drugs to eligible seniors at $50 per month, with analysts projecting blockbuster annual sales for Lilly from the program.
Financial Highlights
Revenue
blockbuster annual sales projected
Outcome Details
Medicare launched a bridge model offering weight loss drugs to eligible seniors at $50 per month as part of MFN drug pricing deal with Trump administration
Importance:6/10
Sentiment:
0.70
GLP-1Medicarepricingobesityweight lossTrump administration
Read the original article
Published by FiercePharma on September 2, 2026 10:04 AM